WE’RE TAKING NEUROLOGY TO A WHOLE NEW LEVEL
Eisai Neurology is aiming to revolutionize drug discovery and develop targeted medicines for some of the world’s most challenging neurological conditions. Read how our dedication and patient interactions influence our approach and help us create hope through innovation.
WE’RE ON A MISSION TO PREVENT AND EVEN REVERSE ALZHEIMER’S DISEASE (AD)
Our 30+ year commitment to addressing AD grows naturally from our human health care mission. It’s one of society’s greatest unmet medical needs, and we’re determined to find precision solutions that go beyond treatment, to prevention and reversal. To that end, we’ve amassed an unparalleled set of capabilities:
- We’re one of the only companies with programs targeting several key areas: amyloid (the main component of plaques found in the brains of people with AD); tau (a protein that’s vital to brain health); neurodegeneration; inflammation; and the clinical symptoms of dementia, such as cognition and sleep-wake rhythm disorder.
- Our rich pipeline includes a wide scope of investigational compounds and diagnostic methods being researched in AD. In addition, we’re exploring novel therapies designed to address clinical symptoms such as cognition and sleep-wake rhythm disorder.
- Eisai and Biogen are jointly researching disease-modifying compounds* for potential treatment of AD.
- Our ground-breaking Center for Genetics Guided Dementia Discovery (G2D2) is focused on delivering a new generation of immunodementia drugs that can bolster the body’s immunity against dementia.
We’re proud to have dedicated more than 30 years to research, development and commercialization in our relentless pursuit of treatments for Alzheimer’s disease and dementia.”
Ivan Cheung Chairman, Eisai Inc. Global President, Neurology Business Group
DISCOVER HOW WE’RE BREAKING THROUGH FOR PEOPLE LIVING WITH:
*All compounds on this page are investigational.